Janssen Reports Results of Amivantamab in P-I CHRYSALIS Study for Metastatic or Unresectable NSCLC and EGFR Exon 20 Insertion Mutations
Janssen Reports MAA Submission to EMA for Cilta-cel to Treat Relapsed/ Refractory Multiple Myeloma
Shots:
- The P-I CHRYSALIS study involves assessing of amivantamab (RP2D of 1050 mg [1400 mg for a patient weight of ≥80 kg]) as a monothx. and in combination with lazertinib in 460 patients with metastatic or unresectable NSCLC and EGFR exon 20 insertion mutations whose disease progressed on or after platinum-based CT
- Results: ORR (40%); mPFS (8.3 mos.); mOS (22.8 mos.), clinical benefit rate (74%), mDoR (11.1 mos.). The data showed robust activity and durable responses with a tolerable and manageable safety profile
- The company has filed regulatory submissions in the US and EU seeking approval of amivantamab
Click here to read full press release/ article | Ref: PRNewswire | Image: The Pharma Letter